The combination of various treatments has been demonstrated to be effective in breast cancer, since co-inhibition of Aurora-A and FOXM1 effectively breaks the feedback loop and interferes with the kinase and non-kinase functions of Aurora-A in TNBC, targeting, respectively, both cytoplasmic (kinase dependent) and nuclear (kinase independent) functions [33]. The gene discussed is FOXM1; the disease is breast carcinoma.